Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KER-012

Recombinant protein · developed by Keros Therapeutics

Phase 2 Most advanced trial (none active)
KROS Developer
1 Registered trials

What is KER-012?

KER-012 is a drug studied in pulmonary arterial hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Recombinant protein
Therapy area
Respiratory
Developer
Keros Therapeutics, Inc. (KROS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05975905 Phase 2 Pulmonary Arterial Hypertension Terminated KROS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pulmonary Arterial Hypertension

More from Keros Therapeutics

Follow KROS, the company behind KER-012

See KROS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KROS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.